MIRA Pharmaceuticals (NASDAQ:MIRA) Posts Earnings Results, Misses Expectations By $1.07 EPS

MIRA Pharmaceuticals (NASDAQ:MIRA) released its quarterly earnings data on Tuesday. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($1.07), Zacks reports.

MIRA Pharmaceuticals Stock Down 5.6%

Shares of MIRA Pharmaceuticals stock traded down $0.08 during trading hours on Thursday, reaching $1.35. 534,203 shares of the company’s stock were exchanged, compared to its average volume of 1,714,416. The business has a fifty day moving average of $1.43 and a two-hundred day moving average of $1.39. The company has a market capitalization of $25.74 million, a P/E ratio of -2.76 and a beta of 1.72. MIRA Pharmaceuticals has a 1 year low of $0.73 and a 1 year high of $2.45.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in MIRA Pharmaceuticals stock. XTX Topco Ltd bought a new stake in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 21,873 shares of the company’s stock, valued at approximately $26,000. XTX Topco Ltd owned about 0.13% of MIRA Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 35.16% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on MIRA. Wall Street Zen raised shares of MIRA Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, October 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, MIRA Pharmaceuticals presently has a consensus rating of “Sell”.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.